Genetic Changes in Epithelial Solid Neoplasia

Cancer Research

Volumn 54, Issue 13, 1994, Pages 3398-3406

  Rodriguez, Eduardo ^a   Sreekantaiah, Chandrika ^a   ChagantI, R S K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER GENETICS; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CYTOGENETICS; EPITHELIUM TUMOR; HETEROZYGOSITY; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME DISORDERS; GENE AMPLIFICATION; GENES, TUMOR SUPPRESSOR; HUMAN; INCIDENCE; NEOPLASMS; PROGNOSIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028284333     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (146)

1. Chaganti, R.S.K., and Klein, E.A. The cytogenetic basis for molecular analysis of leukemia, lymphoma and solid tumors. In: J. Cossman (ed.), Molecular Genetics in Cancer Diagnosis, pp. 73-104. New York: Elsevier Publishing, 1991.
2. Mitelman, F. Catalog of Chromosome Aberrations in Cancer. New York: Wiley-Liss, Inc., 1991.
3. Harnden, D.G., and Klinger, H.P. (eds.). An International System for Human Cytogenetic Nomenclature. Basel: S. Karger AG, 1985.
4. Mitelman, F. (ed.). ISCN: Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature, Basel: S. Karger AG, 1991.
5. Heim, S., Mandahl, N., Jin, Y., Stromblad, S., Lindstrom, E., Salford, L.G., and Mitelman, F. Trisomy 7 and sex chromosome loss in human brain tissue. Cytogenet. Cell Genet., 52: 136-138, 1989.
6. Elfving, P., Cigudosa, J.C., Lundgren, Limon, J., Mandahl, N., Kristofersson, U., Heim, S., and Mitelman, F. Trisomy 7, trisomy 10, and loss of the Y chromosome in short-term cultures of normal kidney tissue. Cytogenet. Cell Genet., 53: 123-125, 1990.
7. Dal Cin, P., Aly, M.S., Delabie, J., Ceuppens, J.L., Van Gool, S., Van Damme, B., Baert, L., Van Poppel, H., and Van Den Berghe, H. Trisomy 7 and trisomy 10 characterize subpopulations of tumor-infiltrating lymphocytes in kidney tumors and in the surrounding kidney tissue. Proc. Natl. Acad. Sci. USA, 89: 9744-9748, 1992.
8. Seizinger, B.R., Klinger, H.P., Junien, C., Nakamura, Y., Le Beau, M., Cavenee, W., Emmanuel, B., Ponder, B., Naylor, S., Mitelman, F., Louis, D., Menon, A., Newsham, I., Decker, J., Kaelbling, M., Henry, I., and Deimling, A. v. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet. Cell Genet., 58: 1080-1096, 1991.
9. Sreekantaiah, C., and Bhargava, M.K. Double minute chromatin bodies in carcinoma of the human cervix uteri. Cancer Genet. Cytogenet., 58: 134-140, 1992.
10. Bello, M.J., Moreno, S., and Rey, J.A. Involvement of 9p in metastatic ovarian adenocarcinomas. Cancer Genet. Cytogenet., 45: 223-229, 1990.
11. Vandamme, B., Lissens, W., Amfo, K., De Sutter, P., Bourgain, C., Vamos, E., and De Grève, J. Deletion of chromosome 11p. 3-11p. 5.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res., 52: 6646-6652, 1992.
12. Sandberg, A.A. Chromosome changes in bladder cancer: clinical and other correlations. Cancer Genet. Cytogenet., 19: 163-175, 1986.
13. Babu, V.R., Lutz, M.D., Miles, B.J., Farah, R.N., Weiss, L., and Van Dyke, D.L. Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res., 47: 6800-6805, 1987.
14. Trent, J., Yang, J.M., Emerson, J., Dalton, W., McGee, D., Massey, K., Thompson, F., and Villar, H. Clonal chromosome abnormalities in human breast carcinomas II. Thirty-four cases with metastatic disease. Genes Chromosomes Cancer, 7: 194-203, 1993.
15. Dal Cin, P., Gaeta, J., Huben, R., Frederick, P.L., Prout, G.R., and Sandberg, A.A. Renal cortical tumors. Cytogenetic characterization. Am. J. Clin. Pathol., 92: 408-414, 1989.
16. Kovacs, G., Fuzesi, L., Emanuel, A., and Kung, H.F. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer, 3: 249-255, 1991.
17. Kovacs, G., Erlandsson, R., Boldog, F., Ingvarsson, S., Müller-Brechlin, R., Klein, G., and Sumegi, J. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc. Natl. Acad. Sci. USA, 85: 1571-1575, 1988.
18. Hughson, M.D., Johnson, L.D., Silva, F.G., and Kovacs, G. Nonpapillary and papillary renal cell carcinoma: a cytogenetic and phenotypic study. Mod. Pathol., 6: 449-455, 1993.
19. Pandis, N., Heim, S., Bardi, G., Idevall, I., Mandahl, N., and Mitelman, F. Chromosome analysis of 20 breast carcinomas: cytogenetic multiclonality and karyotypicpathologic correlations. Genes Chromosomes Cancer, 6: 51-57, 1993.
20. Pejovic, T., Himmelmann, A., Heim, S., Mandahl, N., Flodérus, U.M., Furgyik, S., Elmfors, B., Helm, G., Willén, H., and Mitelman, F. Prognosis impact of chromosome aberrations in ovarian cancer. Br. J. Cancer, 65: 282-286, 1991.
21. Pejovic, T., Heim, S., Mandahl, N., Baldetorp, B., Elmfors, B., Floderus, U.M., Furgyik, S., Helm, G., Himmelmann, A., Willen, H., and Mitelman, F. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer, 4: 58-68, 1992.
22. Wijkström, H., Granberg-Öhman, I., and Tribukait, B. Chromosomal and DNA patterns in transitional cell bladder carcinoma. A comparative cytogenetic and flowcytofluorometric DNA study. Cancer (Phila.), 53: 1718-1723, 1984.
23. Pauwels, P.E., Smeets, A.W.G.B., Schapers, R.F.M., Geraedts, J.P.M., and Debniyne, M.J. Grading in superficial bladder cancer. (2) Cytogenetic classification. Br. J. Urol., 61: 135-139, 1988.
24. Perucca, D., Szepetowski, P., Simon. M.P., and Gaudray, P. Molecular genetics of human bladder carcinomas. Cancer Genet. Cytogenet., 49: 143-156, 1990.
25. Friend, S.H., Bernards, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M., Albert, D.M., and Dryja, T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (Lond.), 323: 643-646, 1986.
26. Lee, W.H., Bookstein, R., Hong, F., Young, L.J., Shew, J.Y., and Lee, E. Y.H.P. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science (Washington DC), 235: 1394-1399, 1987.
27. Fearon, E.R., Cho, K.R., Nigro, J.M., Kern, S.E., Simmons, J.W., Ruppert, J.M., Hamilton, S.R., Preisinger, A.C., Thomas, G., Kinzler, K.W., and Volgelstein, B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (Washington DC), 247: 49-56, 1990.
28. Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., van Tuinen, P., Ledbetter, D.H., Baker, D.F., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p. 3 gene mutations in colorectal carcinomas. Science (Washington DC), 244: 217-221, 1989.
29. Kinzler, K.W., Nilbert, M.C., Su, L.K., Vogelstein, B., Bryan, T.M., Levy, D.B., Smith, K.J., Preisinger, A.C., Hedge, P., McKechnie, D., Finniear, R., Markham, A., Groffen, J., Boguski, M.S., Altschul, S.F., Horii, A., Ando, H., Miyoshi, Y., Miki, Y., Nishisho, I., and Nakamura, Y. Identification of FAP locus genes from chromosome 5q21. Science (Washington DC), 253: 661-665, 1991.
30. Rose, E.A., Glaser, T., Jones, C., Smith, C.L., Lewis, W.H., Call, K.M., Minden, M., Champagne, E., Bonetta, L., Yeger, H., and Housman, D.E. Complete physical map of the WAGR region of 11p. 3 localizes a candidate Wilms' tumor gene. Cell, 60: 495-508, 1990.
31. Wallace, M.R., Marchuk, D.A., Andersen, L.B., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (Washington DC), 249: 181-186, 1990.
32. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.M., Orcutt, M.L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F.U.H., Wei, M.H., Chen, F., Glenn, G., Choyke, P., Walther, M.M., Weng, Y., Duan, D.S.R., Dean, M., Glavac, D., Richards, F.M., Crossey, P.A., Ferguson-Smith, M.A., Le Paslier, D., Chumakov, I., Cohen, D., Chinault, A.C., Maher, E.R., Linehan, W.M., Zbar, B., and Lerman M.I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.
33. Bevilacqua, G., Sobel, M.E., Liotta, L.A., and Steeg, P.S. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res., 49: 5185-5190, 1989.
34. Chiba, I., Takahashi, T., Nau, M.M., D'Amico, D., Curiel, D.T., Mitsudomi, T., Buchhagen, D.L., Carbone, D., Piantadosi, S., Koga, H., Reissman, P.T., Slamon, D.J., Holmes, E.C., and Minna, J.D. Mutation in the p. 3 gene are frequent in primary resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.
35. Casson, A.G., Mukhopadhyay, T., Cleary, K.R., Ro, J.Y., Levin, B., and Roth, J.A. p. 3 mutations in Barrett's epithelium and esophageal cancer. Cancer Res., 51: 4495-4499, 1991.
36. Levine, A.J., Momand, J., and Finlay, C.A. The p. 3 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
37. Murakami, Y., Hayashi, K., Hirohashi, S., and Sekiya, T. Aberrations of the tumor suppressor p. 3 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res., 51: 5520-5525, 1991.
38. Bennett, W.P., Hollstein, M.C., Metcalf, R.A., Welsh, J.A., He, A., Zhu, S.M., Kusters, I., Resau, J.H., Trump, B.F., Lane, D.P., and Harris, C.C. p. 3 mutations and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res., 52: 6092-6097, 1992.
39. Damico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russel, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., Gazdar, A., and Minna, J.D. High frequency of somatically acquired p. 3 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7: 339-346, 1992.
40. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T., and Terada, M. Frequent association of p. 3 gene mutation in invasive bladder cancer. Cancer Res., 52: 1393-1398, 1992.
41. Kaelbling, M., Burk, R.D., Atkin, N.B., Johnson, A.B., and Klinger, H.P. Loss of heterozygosity on chromosome 17p and mutant p. 3 in HPV-negative cervical carcinomas. Lancet, 340: 140-142, 1992.
42. Kohler, M.F., Berchuck, A., Davidoff A.M., Humphrey, P.A., Dodge, R.K., Iglehart, J.D., Soper, J.T., Clarke-Pearson, D.L., Bast, R.C., Jr., and Marks, J.R. Overexpression and mutation of p. 3 in endometrial carcinoma. Cancer Res., 52: 1622-1627, 1992.
43. Mazars, R., Spinardi, L., BenCheikh, M., Simony-Lafontaine, J., Jeanteur, P., and Theillet C. p. 3 mutations occur in aggressive breast cancer. Cancer Res., 52: 3918-3923, 1992.
44. Miller, C.W., Simon, K., Aslo, A., Kok, k., Yokota, J., Buys, C.H.C.M., Terada, M., and Koeffler, H.P. p. 3 mutations in human lung tumors. Cancer Res., 52; 1695-1698, 1992.
45. Sameshima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., Terada, M., and Yokota, J. Alterations of the p. 3 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene, 7: 451-457, 1992.
46. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C.T., Pastorino, U., Dellaporta, G., and Pierotti, M.A. Deletions of 17p and p. 3 mutations in preneoplastic lesions of the lung. Cancer Res., 52: 6079-6082, 1992.
47. Thompson, A.M., Anderson, T.J., Condie, A., Prosser, J., Chetty, U., Carter, D.C., Evans, H.J., and Steel, C.M. p. 3 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int. J. Cancer, 50: 528-532, 1992.
48. Bookstein, R., MacGrogan, D., Hilsenbeck, S.G., Sharkey, F., and Allred, D.C. p. 3 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 33693373, 1993.
49. Boyle, J.O., Hakim, J., Koch, W., van der Riet, P., Hruban, R.H., Roa, R.A., Correo, R., Eby, Y.J., Ruppert, J.M., and Sidransky, D. The incidence of p. 3 mutations increases with progression of head and neck cancer. Cancer Res., 53: 4477-4480, 1993.
50. Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Sato, C., Tsuruta, K., Maeda, Y., Koike, M., Tanaka, S., Nakamura, Y., Hattori, N., and Miyaki, M. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn. J. Cancer Res., 84: 893-899, 1993.
51. Meling, G.I., Lothe, R.A., Borresen, A.L., Graue, C., Hauge, S., Clausen, O.P.F., and Rognum, T.O. The TP53 tumor suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables. Br. J. Cancer, 67: 93-98, 1993.
52. Milner, B.J., Allan, L.A., Eccles, D.M., Kitchener. H.C., Leonard, R.C.F., Kelly, K.F., Parkin, D.E., and Haites, N.E. p. 3 mutation is a common genetic event in ovarian carcinoma. Cancer Res., 53: 2128-2132, 1993.
53. Uchino, S., Noguchi, M., Ochiai, A., Saito, T., Kobayashi, M., and Hirohashi, S. p. 3 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int. J. Cancer, 54: 759-764, 1993.
54. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p. 3. Science (Washington DC), 249: 912-915, 1990.
55. Chen, P.L., Chen, Y.M., Bookstein, R., and Lee, W.H. Genetic mechanisms of tumor suppression by the human p. 3 gene. Science (Washington DC), 256: 15761580, 1990.
56. Diller, L., Kassel, J., Nelson, C.E., Gryka, M.A., Utwak, G., Gebhardt, N., Bressac, B., Ozturk, M., Baker, S.J., Vogelstein, B., and Friend, S.H. p. 3 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772-5781, 1990.
57. Mercer, W.E., Shields, M.T., Amin, M., Sauve, G.J., Appella, E., Romano, J.W., and Ullrich, S.J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wildtype p. 3. Proc. Natl. Acad. Sci. USA, 87: 6166-6170, 1990.
58. Matozaki, T., Sakamoto, C., Suzuki, T., Matsuda, K., Uchida, T., Nakano, O., Wada, K., Nishisaki, H., Konda, Y., Nagao M., and Kasuga, M. p. 3 gene mutations in human gastric cancer: wild-type p. 3 but not mutant p. 3 suppresses growth of human gastric cancer cells. Cancer Res., 52: 4335-4341, 1992
59. Harbour, J.W., Lai, S.H., Whang-Peng, J., Gazdar, A.F., Minna, J.D., and Kaye, F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (Washington DC), 241: 353-357, 1988.
60. Lee, E.Y.H.P., Shew, J.Y., Bookstein, R., Scully, P., and Lee, W.H. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science (Washington DC), 241: 218-221, 1988.
61. T'Ang, A., Varley, J.M., Chakraborty, S., Murphree, A.L., and Fung, Y.K.T. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science (Washington DC), 242: 263-266, 1988.
62. Bookstein, R., Shew, J.Y., Chen, P.L., Scully, P., and Lee, W.H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science (Washington DC), 247: 712-715, 1990.
63. Hensel, C.H., Hsieh, C.L., Gazdar, A.F., Johnson, B.E., Sakaguchi, A.Y., Naylor, S.L., Lee, W.H., and Lee, E. Y.H.P. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res., 50: 3067-3072, 1990.
64. Ishikawa, J., Xu, H.J., Hu, S.X., Yandell, D.W., Maeda, S., Kamidono, S., Benedict, W.F., and Takahashi, R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res., 51: 5736-5743, 1991.
65. Zbar, B., Brauch, H., Talmadge, C., and Linehan, M. Loss of alleles in loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (Lond.), 327: 721-724, 1987.
66. Kovacs, G., Erlandsson, R., Boldog, F., Ingvarsson, S., Müller-Brechlin, R., Klein, G., and Sümegi, J. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Porc. Natl. Acad. Sci. USA, 85: 1571-1575, 1988.
67. Ogawa, O., Kakehi, Y., Ogawa, K., Koshiba, M., Sugiyama, T., and Yoshida, O. Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. Cancer Res., 51: 949-953, 1991.
68. Cohen, A.J., Li, F.P., Berg, S., Marchetto, D.J., Tsai, S., Jacobs, S.C., and Brown, R.S. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med., 301: 592-595, 1979.
69. Wang, N., and Perkins, L. Involvement of band 3p. 4 in t(3;8) hereditary renal carcinoma. Cancer Genet. Cytogenet., 11: 469-481, 1984.
70. Seizenger, B.R., Rouleau, G.A., Ozelius, L.J., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature (Lond.), 332: 268-269, 1988.
71. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.M., Orcutt, M.L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, H., Wei, M.H., Chen, F., Glenn, G., Choyke, P., Walther, M.M., Weng, Y., Duan, D.S.R., Dean, M., Glavac, D., Richards, F.M., Crossey, P.A., Ferguson-Smith, M.A., Le Paslier, D., Chumakov, I., Cohen, D., Chinault, A.C., Maher, E.R., Linehan, W.M., Zbar, B., and Lerman, M.I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.
72. Yokoyama, S., Yamakawa, K., Tsuchiya, E., Murata, M., Sakiyama, S., and Nakamura, Y. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res., 52: 873-877, 1992.
73. Yamakawa, K., Takahashi, T., Horio, Y., Horio, Y., Murata, Y., Takahashi, E., Hibi, K., Yokoyama, S., Ueda, R., Takahashi, T., and Nakamura, Y. Frequent homozygous deletions in lung Cancer cell lines detected by a DNA marker located at 3p. 1.3-p. 2. Oncogene, 8: 327-330, 1993.
74. Yokota, J., Tsukada, Y., Nakajima, T., Gotoh. M., Shimosato, Y., Mori, N., Tsunokawa, Y., Sugimura, T., and Terada, M. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res., 49: 3598-3601, 1989.
75. Kohno, T., Takayama, H., Hamaguchi, M., Takano, H., Yamaguchi, N., Tsuda, H., Hirohashi, S., Vissing, H., Shimizu, M., Oshimura, M., and Yokota, J. Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene, 8: 18251832, 1993.
76. Sato, T., Akiyama, F., Sakamoto, G., Kasumi, F., and Nakamura, Y. Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res., 51: 57945799, 1991.
77. Latif, F., Fivash, M., Glenn, G., Tory, K., Orcutt, M.L., Hampsch, K., Delisio, J., Lerman, M., Cowan, J., Beckett, M., and Weichselbaum, R. Chromosome 3p deletions in head and neck statistical ascertainment of allelic loss. Cancer Res., 52: 1451-1456, 1992.
78. Gailani, M.R., Bale, S.J., Leffell, D.J., DiGiovanna, J.J., Peck, G.L., Poliak, S., Drum, M.A., Pastakia, B., McBride, O.W., Kase, R., Greene, M., Mulvihill, J.J., and Bale, A.E. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell, 69: 111-117, 1992.
79. Morton, R.A., Ewing, C.M., Nagafuchi, A., Tsukita, S., and Isaacs, W.B. Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res., 53: 3585-3590, 1993.
80. Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Nakamura, V., White, R., Smith, A.M., and Bos, J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
81. Kikuchi-Yanoshita, R., Konishi, M., Ito, S., Seki, M., Tanaka, K., Maeda, Y., Lino, H., Fukayama, M., Koike, M., Mori, T., Sakuraba, H., Fukunari, H., Iwama, T., and Miyaki, M. Genetics changes of both p. 3 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res., 52: 3965-3971, 1992.
82. Miyaki, M., Seki, M., Okamoto, M., Yamamaka, A., Maeda, Y., Tanaka, K., Kikuchi, R., Iwama, T., Ikeuchi, T., Tonomura, A., Nakamura, Y., White, R., Miki, Y., Utsunomiya, J., and Koike, M. Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res., 50: 7166-7173, 1990.
83. Fujiwara, Y., Emi, M., Ohata, H., Kato, Y., Nakajima, T., Mori, T., and Nakamura, Y. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res., 53: 1172-1174, 1993.
84. Lipkin, M. Biomarkers of increased susceptibility of gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res., 48: 235-245, 1988.
85. Fearon, E.R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
86. Blount, P.L., Meltzer, S.J., Yin, J., Huang, Y., Krasna, M.J., and Reid, B.J. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc. Natl. Acad. Sci. USA, 90: 3221-3225, 1993.
87. Dodson, M.K., Hartmann, L.C., Cliby, W.A., DeLacey, K.A., Keeney, G.L., Ritland, S.R., Su, J.Q., Podratz, K.C., and Jenkins, R.B. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res., 53: 4456-4460, 1993.
88. Fearon, E.R., Feinberg, A.P., Hamilton, S.H., and Vogelstein, B. Loss of genes on the short arm of chromosoeme 11 in bladder cancer. Nature (Lond.), 318: 377-380, 1985.
89. Olumi, A.F., Tsai, Y.C., Nichols, P.W., Skinner D.G., Cain, D.R., Bender, L.I., and Jones, P.A. Allelic loss of chromosomes 17p distinguishes high grade from low-grade transitional cell carcinomas of the bladder. Cancer Res., 50: 7081-7083, 1990.
90. Cairns, P., Proctor, A.J., and Knowles, M.A. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene, 6: 2305-2309, 1991.
91. Presti J.C. Jr., Reuter, V.E., Galan, T., Fair, W.R., and Cordon-Cardo, C. Molecular genetic alterations in superficial and locally advanced human bladder. Cancer Res., 51: 5405-5409, 1991.
92. Dalbagni, G., Presti, J.C., Jr., Reuter, V.E., Zhang, Z.F., Sarkis, A.S., Fair, W.R., and Cordon-Cardo, C. Moleclar genetic alterations of chromosomes 17 and p. 3 nuclear overexpression in human bladder cancer. Diagn. Mol. Pathol., 2: 4-13, 1993.
93. Sano, T., Tsujino, T., Yoshida, K., Nakayama, H., Haruma, K., Ito, H., Nakamura, Y., Kajiyama, G., and Tahara, E. Frequent loss of heterozygosity on chromosome lq, 5q, and 17p in human gastric carcinomas. Cancer Res., 51: 2926-2931, 1991.
94. Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Sato, C., Tsuruta, K., Maeda, Y., Koike, M., Tanaka, S., Nakamura, Y., Hattori, N., and Miyaki, M. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn. J. Cancer Res., 84: 893-899, 1993.
95. Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., and Nakamura, Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res., 50: 7184-7189, 1990.
96. Takita, K., Sato, T., Miyagi, M., Watatani, M., Akiyama, F., Sakamoto, G., Kasumi, F., Abe, R., and Nakamura, Y. Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. Cancer Res., 52: 3914-3917, 1992.
97. Lindblom, A., Rotstein, S., Skoog, L., Nordenskjöld, M., and Larsson, C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res., 53: 3707-3711, 1993.
98. Bièche, I., Champeme, M.H., Merlo, G., Larsen, C.J., Callahan, R., Lidereau, R. Loss of heterozygosity of the L-myc oncogene in human breast tumors. Hum. Genet., 85: 101-105, 1990.
99. Bièche, I., Champéme, M.H., Matifas, F., Hacène, K., Callahan, R., and Lidereau, R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet, 339: 139-143, 1992.
100. Tsuda, H., Zhang, W., Shimosato, Y., Yokota, J., Terada, M., Sugimura, T., Miyamura, T., and Hirohashi, S. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA, 87: 6791-6794, 1990.
101. Emi, M., Fujiwara, Y., Ohata, H., Tsuda, H., Hirohashi, S., Koike, M., Miyaki, M., Monden, M., and Nakamura, Y. Allelic loss at chromosome band 8p. 1.3-p. 2 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer, 7: 152-157, 1993.
102. Kakehi, Y., and Yoshida, O. Restriction-fragment-length polymorphism of the L-myc gene and susceptibility to metastasis in renal-cancer patients. Int. J. Cancer, 43: 391-394, 1989.
103. Kawashima, K., Nomura, S., Hirai, H., Fukushi, S., Karube, T., Takeuchi, K., Naruke, S., and Nishimura, S. Correlation of L-myc RFLP with metastasis, prognosis and multiple cancer in lung-cancer patients. Br. J. Cancer, 50: 557-561, 1992.
104. Shibuya, M., Yokota, J., and Ueyama, Y. Amplification and expression of a cellular oncogene (c-myc) in human gastric adenocarcinoma cells. Mol. Cell. Biol., 5: 414-418, 1985.
105. Koda, T., Matsushima, S., Sasaki, A., Danjo, Y., and Kaninuma, M. C-myc gene amplification in primary stomach cancer. Jpn. J. Cancer Res., 76: 551-554, 1985.
106. Bos, J.L., Verlaan de Vries, M., Marshall, C.J., Veeneman, G.H., Van Boom, J.H., and Van der Eb, A J. A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res., 14: 1209-1217, 1986.
107. Yokota, J., Yamamoto, T., Toyoshima, K., Terada, M., Sugimura, T., Battifora, H., and Cline, M.J. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet, 1: 765-767, 1986.
108. Yoshida, M.C., Wada, M., Satoh, H., Yoshida, T., Sakamoto, H., Miyagawa, K., Yokota, J., Koda, T., Kakinuma, M., Sugimura, T., and Terada, M. Human HST/ (HSTF1) gene maps to chromosome band 11q13 and coamplification with the INT2 gene in human cancer. Proc. Natl. Acad. Sci. USA, 85: 4861-4864, 1988.
109. Park, J.B., Rhim, J.S., Park, S.C., Kimm, S.W., and Kraus, M.H. Amplification, overexpression and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas, Cancer Res., 49: 6605-6609, 1989.
110. Borg, å., Tandon, A.K., Sigurdsson, H., Qark, G.M., Fearon, M., Fuqua, S.A.W., Killander, D., and McGuire, W.L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res., 50: 4332-4337, 1990.
111. Hirohashi, S., and Sugimura, T. Genetic alterations in human gastric cancer. Cancer Cells (Cold Spring Harbor), 3: 49-52, 1991.
112. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wang, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ulrich, A., and Press, M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
113. Berchuck, A., Kamel, A., Whitaker, R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
114. Sasano, H., Garrett, C.T., Wilkinson, D.S., Silverberg, S., Comerford, J., and Hyde, J. Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum. Pathol., 21: 382-391, 1990.
115. Borg, å., Baldetorp, B., Femö, M., Olsson, H., and Sigurdsson, H. C-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int. J. Cancer, 51: 687-691, 1992.
116. Borg, A., Sigurdsson, H., Qark, G.M., et al. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer, 63: 136-142, 1991.
117. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
118. Winstanley, J., Cooke, T., Murray, G.D., et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br. J. Cancer, 63: 447-450, 1991.
119. Toikkanen, S., Helin, H., Isola, J., and Joensuu, H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year follow up. J. Cin. Oncol., 10: 1044-1048, 1992.
120. Descotes, F., Pavy, J.J., and Adessi, G.L. Human breast cancer: Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res., 13: 119-124, 1993.
121. Klijn, J.G.M., Berns, P.M.J.J., Schmitz, P.I.M., and Foekens, J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev., 13: 3-17, 1992.
122. Ali, I.U., Campbell, G., Lidereau, R., and Callahan, R. Amplification of c-erbB2 and aggressive human breast tumors. Science (Washington DC), 240: 1795-1798, 1988.
123. Shou, D.J., Ahuja, H., and Qine, M.J. Proto-oncogene abnormalities in human breast cancer: c-erbB2 amplification does not correlate with recurrence of disease. Oncogene, 4: 105-108, 1988.
124. Van de Vijiver, M., Peterse, J.L., Mooi, W.J., Wisman, P., Lomans, J., Delesio, O., and Nusse, R. Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer. N. Engl. J. Med., 319: 1239-1245, 1988.
125. Zhou, D.J., Ahuja, H., and Cline, M.J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene, 4: 105-108, 1988.
126. Qark, G.M., and McGuire, W.L. Follow up study of HER-2/neu amplification in primary breast cancer. Cancer Res., 51: 944-948, 1991.
127. Tsuda, T., Tahara, E., Kajiyama, G., Sakamoto, H., Terada, M., and Sugimura, T. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res., 49: 5505-5508, 1989.
128. Zhou, J., Taguchi, T., Siegfried J.M., Jhanwar, S.G., Resau, J., and Testa, J.R. Characterization of 9q;15q whole-arm translocation derivatives in non-small cell lung carcinomas by fluorescence in situ hybridization. Cancer Genet. Cytogenet., 69: 1-6, 1993.
129. Meltzer, P.S., Guan, X.Y., Burgess, A., and Trent, J.M. Rapid generation of region specific probes by chromosome microdissection and their application. Nat. Genet., 1: 24-28, 1992.
130. Micale, M.A., Sanford, J.S., Powell, I.J., Sakr, W.A., and Wolman, S.R. Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: paraffin FISH versus metaphase analysis. Cence Genet. Cytogenet., 69: 7-12, 1993.
131. Poddighe, P.J., Ramaekers, F.C.S., and Hopman, A.H.N. Interphase cytogenetics of tumors. J. Pathol., 166: 215-224, 1992.
132. Kallioniemi, O.P., Kallioniemi, D., Rutovitz, D., Sudar, D., Gray, J.W., Waldeman, F., and Pinkel, D. Comparative genomic hybridization: a new method based on isolated DNA to determine gains and losses of DNA sequences anywhere in the genome in a single hybridization (abstract). Am. J. Hum. Genet., 51: A23, 1992.
133. Du Manoir, S., Speicher, M.R., Joos, S., Schröck, E., Popp, S., Dohner, H., Kovacs, G., Robert-Nicoud, M., Lichter, P., and Cremer, T. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum. Genet., 90: 590-610, 1993.
134. Weissenbach, J., Gyapay, G., Dib, C., Vignal, A., Morissette, J., Millasseau, P., Vaysseix, G., and Lathrop M. A second-generation linkage map of the human genome. Nature (Lond.), 359: 794-801, 1992.
135. Peltomaki, P., Lothe, R.A., Aaltonen, L.A., Pylkkanen, L., Nystrom-Lahti, M., Seruca, R., David, L., Holm, R., Ryberg, D., Haugen, A., Brogger, A., Borresen, A.L., and de la Chapelle, A. Microsatellite instability is associated with tumors that characterize the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer Res., 53: 5853-5855, 1993.
136. Ionov, Y., Peinado, M.A., Malkhosyan, S., Shibata, D., and Perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (Lond.), 363: 558-561, 1993.
137. Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., and Vogelstein, B. Mutations of mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75: 1215-1225, 1993.
138. Gonzalez-Zulueta, M., Ruppert, J.M., Tokino, K., Tsai, Y.C., Spruck, C.H.I., Miyao, N., Nichols, P.W., Hermann, G.G., Horn, T., Steven, K., Summerhayes, I.C., Sidransky, D., and Jones, P.A. Microsatellite instability in bladder cancer. Cancer Res., 53: 5620-5623, 1993.
139. Bigner, S.H., Mark, J., and Bigner, D.D. Cytogenetics of human brain tumors. Cancer Genet. Cytogenet., 47: 141-154, 1990.
140. Sreekantaiah, C., Ladanyi, M., Rodriguez, E., and Chaganti, R.S.K. Chromosomal aberrations insoft tissue tumors: relevance to diagnosis, classification and molecular mechanisms. Am. J. Pathol., in press, 1994.
141. Offit, K., and Chaganti, R.S.K. Chromosomal aberrations in non-Hodgkin's lymphoma: biological and clinical correlations. Hematol./Oncol. Clin. North Am., 5: 853-869, 1991.
142. Chaganti, R.S.K., Rodriguez, E., and Bosl, G.J. Cytogenetics of male germ cell tumors. Urol. Clin. North Am., 20: 55-66, 1993.
143. Rodriguez, E., Houldsworth, J., Reuter, V.E., Trent, J.M., Bosl, G.J., and Chaganti, R.S.K. Molecular cytogenetic analysis of i(12p) negative human male germ cell tumors. Genes Chromosomes Cancer, 8: 230-236, 1993.
144. Narroz, H., van der Riet, P., Hruban, R.H., Koch, W., Ruppert, J.M., Sidransky, D. Allelotype of head and neck squamous cell carcinoma. Cancer Res., 54: 1152-1155, 1994.
145. Knowels, M.A., Elder, P.A., Williamson, M., Cairns, J.P., Shaw, M.E., Law, M.G. Allelotype of human bladder cancer. Cancer Res., 54: 531-538, 1994.
146. Kamb, A., Gruis, N.A., Weaver-Feldhaus, Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S. III., Johnson, B.E., Skolnick, M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436-440, 1994.